Symptomtext
patient inadvertently administering extra dose of FLUZONE HIGH DOSE QIV in one flu season with no reported adverse event; Initial information received on 07-Nov-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 74 years old female patient who inadvertently administered extra dose of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] in one flu season with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 29-Sep-2023, the patient received 0.7 mL dose 1 of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (lot UT8157CA and expiry date: 30-Jun-2024) (Frequency = ONCE), (Strength = FLUZONE HIGH DOSE) via intramuscular route in the left deltoid and On 26-Oct-2023 she also received 0.7 mL dose 2 of the same vaccine. On 26-Oct-2023, the patient inadvertently administering extra dose of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE in one flu season with no reported adverse event (extra dose administered) (latency: 28 days). This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.